BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2575783)

  • 1. The multidrug resistance gene in renal cell carcinoma.
    Klein EA
    Semin Urol; 1989 Nov; 7(4):207-14. PubMed ID: 2575783
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma.
    Chapman AE; Goldstein LJ
    Semin Oncol; 1995 Feb; 22(1):17-28. PubMed ID: 7855615
    [No Abstract]   [Full Text] [Related]  

  • 3. Multidrug resistance.
    Moscow JA; Cowan KH
    Cancer Chemother Biol Response Modif; 1991; 12():91-109. PubMed ID: 1681846
    [No Abstract]   [Full Text] [Related]  

  • 4. [GP-170 glycoprotein and resistance to chemotherapy].
    Lazarowski AJ
    Medicina (B Aires); 1991; 51(3):279-80. PubMed ID: 1687986
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer.
    Srinivasan R; Linehan WM
    J Clin Oncol; 2005 Jan; 23(3):410-2. PubMed ID: 15572728
    [No Abstract]   [Full Text] [Related]  

  • 6. The multidrug resistance phenotype in human cancer.
    Cordon-Cardo C; O'Brien JP
    Important Adv Oncol; 1991; ():19-38. PubMed ID: 1678363
    [No Abstract]   [Full Text] [Related]  

  • 7. [Perspectives on modulation of chemoresistance of malignant diseases].
    Allerödder HP; Ukena D; Sybrecht GW
    Pneumologie; 1993 Sep; 47(9):513-7. PubMed ID: 7901849
    [No Abstract]   [Full Text] [Related]  

  • 8. Multidrug resistance.
    Moscow JA; Cowan KH
    Cancer Chemother Biol Response Modif; 1990; 11():97-114. PubMed ID: 1977437
    [No Abstract]   [Full Text] [Related]  

  • 9. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
    Gardner TA; Logan T
    J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
    [No Abstract]   [Full Text] [Related]  

  • 10. Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788.
    Efferth T; Dunn TA; Berlion M; Langenbahn H; Pommerenke EW; Volm M
    Anticancer Res; 1993; 13(4):905-8. PubMed ID: 8102519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor resistance to multiple antineoplastic agents mediated by glycoprotein P: from the laboratory to the clinical field].
    González-Manzano R
    Med Clin (Barc); 1994 Apr; 102(13):506-15. PubMed ID: 7911549
    [No Abstract]   [Full Text] [Related]  

  • 12. Multidrug resistance mediated by P-glycoprotein in haematological malignancies.
    Pasman PC; Schouten HC
    Neth J Med; 1993 Jun; 42(5-6):218-31. PubMed ID: 8104318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glycoprotein in multidrug-resistant malignancies--clinical implications].
    Ellis A; Lishner M; Manor J; Ravid M
    Harefuah; 1994 Mar; 126(6):334-7. PubMed ID: 7910806
    [No Abstract]   [Full Text] [Related]  

  • 14. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene.
    Mickisch GH; Merlino GT; Aiken PM; Gottesman MM; Pastan I
    J Urol; 1991 Aug; 146(2):447-53. PubMed ID: 1677434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetic events associated with renal cell carninoma and its implication to treatment by molecular target therapy.
    Kishida T; Yao M; Uemura H; Ohlmann C; Tomita Y; Bukowski RM; Naito S
    Int J Urol; 2010 Mar; 17(3):198-205. PubMed ID: 20409215
    [No Abstract]   [Full Text] [Related]  

  • 16. Multiple drug resistance in cancer therapy.
    Schneider E; Cowan KH
    Med J Aust; 1994 Mar; 160(6):371-3. PubMed ID: 7907772
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy].
    Junker K; Sanjmyatav J; Heinze C; Walter M; Heinzelmann J; Wunderlich H; Schubert J; Steiner T
    Urologe A; 2008 Sep; 47(9):1187-9. PubMed ID: 18688592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Multidrug resistance in hematological malignancies: prognostic significance and the effect of resistance-modulating drugs].
    Sonneveld P; te Boekhorst PA
    Ned Tijdschr Geneeskd; 1994 Mar; 138(10):508-12. PubMed ID: 7908127
    [No Abstract]   [Full Text] [Related]  

  • 19. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
    Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
    Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in chemotherapy for renal cell carcinoma.
    Huben RP
    Semin Urol; 1992 Feb; 10(1):16-22. PubMed ID: 1565899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.